176 related articles for article (PubMed ID: 7577661)
1. The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors.
Pollack IF; Kawecki S
Pediatr Neurosurg; 1995; 22(6):281-8. PubMed ID: 7577661
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen.
Baltuch GH; Couldwell WT; Villemure JG; Yong VW
Neurosurgery; 1993 Sep; 33(3):495-501; discussion 501. PubMed ID: 8413883
[TBL] [Abstract][Full Text] [Related]
3. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro.
Pollack IF; Randall MS; Kristofik MP; Kelly RH; Selker RG; Vertosick FT
Cancer Res; 1990 Nov; 50(22):7134-8. PubMed ID: 2224848
[TBL] [Abstract][Full Text] [Related]
4. The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro.
Pollack IF; Kawecki S
J Neurooncol; 1997 Feb; 31(3):255-66. PubMed ID: 9049854
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood.
Pollack IF; DaRosso RC; Robertson PL; Jakacki RL; Mirro JR; Blatt J; Nicholson S; Packer RJ; Allen JC; Cisneros A; Jordan VC
Clin Cancer Res; 1997 Jul; 3(7):1109-15. PubMed ID: 9815790
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line.
Mastronardi L; Farah JO; Puzzilli F; Ruggeri A
Clin Neurol Neurosurg; 1998 Jun; 100(2):89-93. PubMed ID: 9746294
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of radiosensitivity by tamoxifen in C6 glioma cells.
Zhang W; Yamada H; Sakai N; Niikawa S; Nozawa Y
Neurosurgery; 1992 Oct; 31(4):725-9; discussion 729-30. PubMed ID: 1407459
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas.
Couldwell WT; Weiss MH; Law RE; Hinton DR
J Neurosurg; 1995 Mar; 82(3):461-8. PubMed ID: 7861225
[TBL] [Abstract][Full Text] [Related]
9. Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.
Weller M; Trepel M; Grimmel C; Schabet M; Bremen D; Krajewski S; Reed JC
Neurol Res; 1997 Oct; 19(5):459-70. PubMed ID: 9329022
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.
Bredel M; Pollack IF; Freund JM; Hamilton AD; Sebti SM
Neurosurgery; 1998 Jul; 43(1):124-31; discussion 131-2. PubMed ID: 9657198
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
12. Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways.
Pollack IF; Randall MS; Kristofik MP; Kelly RH; Selker RG; Vertosick FT
J Neurosurg; 1990 Jul; 73(1):98-105. PubMed ID: 2161913
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Chen TC; Su S; Fry D; Liebes L
Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
[TBL] [Abstract][Full Text] [Related]
14. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs.
Rabinowicz AL; Hinton DR; Dyck P; Couldwell WT
Epilepsia; 1995 May; 36(5):513-5. PubMed ID: 7614929
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro.
Vertosick FT; Selker RG; Randall MS; Kristofik MP; Rehn T
J Neurooncol; 1994; 19(2):97-103. PubMed ID: 7964994
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C.
Couldwell WT; Antel JP; Yong VW
Neurosurgery; 1992 Oct; 31(4):717-24; discussion 724. PubMed ID: 1407458
[TBL] [Abstract][Full Text] [Related]
17. Disparity in expression of protein kinase C alpha in human glioma versus glioma-derived primary cell lines: therapeutic implications.
Zellner A; Fetell MR; Bruce JN; De Vivo DC; O'Driscoll KR
Clin Cancer Res; 1998 Jul; 4(7):1797-802. PubMed ID: 9676858
[TBL] [Abstract][Full Text] [Related]
18. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report.
Zhang W; Hinton DR; Surnock AA; Couldwell WT
Neurosurgery; 1996 Mar; 38(3):587-90; discussion 590-1. PubMed ID: 8837815
[TBL] [Abstract][Full Text] [Related]
19. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Pollack IF; Kawecki S; Lazo JS
J Neurosurg; 1996 Jun; 84(6):1024-32. PubMed ID: 8847567
[TBL] [Abstract][Full Text] [Related]
20. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases.
Pollack IF; Claassen D; al-Shboul Q; Janosky JE; Deutsch M
J Neurosurg; 1995 Apr; 82(4):536-47. PubMed ID: 7897512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
